The high disease prevalence, the presentation in older age, a frequently slowly progressing course of disease, and high costs make the diagnosis of and therapy for prostate cancer a special challenge for urologists. Effective prevention of the disease may help to improve some of the problems mentioned above. Two randomised, controlled studies have proved that effective chemoprevention of prostate cancer is viable using 5α-reductase inhibitors (finasteride, dutasteride). Furthermore, there is increasing evidence that other compounds, e. g., selective oestrogen receptor modulators (SERMs), NSAIDs and statins might also be effective. This review investigates potential risks and benefits of chemoprevention including a consideration of health economical aspects. The authors conclude that the options of chemoprevention should be investigated in an open and unbiased way.
Written by:
Schmitz-Dräger BJ, Bismarck E, Schöffski O, Fischer C Are you the author?
Urologie, EuromedClinic, Fürth
Reference: Aktuelle Urol. 2012 May;43(3):157-61
doi: 10.1055/s-0031-1284035
PubMed Abstract
PMID: 22639024
[Article in German]